Independent treatment guide
Local injection lipolysis — and how it differs from GLP-1 medicines
These injections should not share one verdict: prescription deoxycholic acid has trials for fat beneath the chin, Aqualyx has smaller product-specific studies, comparable Lemon Bottle trials are lacking, and GLP-1 medicines treat weight systemically rather than dissolving one chosen fat pocket.
Start here
Local injection lipolysis places a substance directly into subcutaneous fat with the aim of damaging fat cells in that small area. Published Aqualyx studies describe it as a sodium-deoxycholate/deoxycholic-acid-salt formulation. The best randomised evidence, however, concerns ATX-101: a different, defined prescription deoxycholic-acid formulation studied beneath the chin.
Lemon Bottle is another branded product, not a synonym for deoxycholic acid or Aqualyx. We did not identify comparable high-quality, product-specific clinical trials in this evidence search. A 2025 FDA warning letter concerned a US distributor selling LemonBottle Ampoule Solution as an unapproved drug; that is US regulatory action, not proof of the product’s UK legal status.
GLP-1 and dual GIP/GLP-1 medicines such as semaglutide and tirzepatide are different again. They are prescription medicines used for diabetes and, for authorised products and eligible patients, weight management. They alter appetite and metabolism across the body; they do not selectively dissolve fat at an injection site.
First decide whether the goal is a small local contour change or clinically supported overall weight management. Then assess the exact product on its own evidence. “It is an injection” is not a meaningful category.
What it may help with
What it will not do
Know what is being compared
Related names and similar delivery methods can hide major differences. These products should not share one set of claims, consent information or expectations.
Local deoxycholate formulation
Injected into a selected subcutaneous fat pocket for local contouring.
A small published study involved 7 women and 14 inner-knee fat pads; other reports include small series and uses outside cosmetic contouring. This is much thinner evidence than the ATX-101 trial programme.
Do not describe Aqualyx simply as “the same as Kybella”. Formulation, product status, body area and technique matter. Published case reports include necrosis, infection and chronic nodules after deoxycholate injections.
Studied medicine for submental fat
A defined formulation studied to reduce moderate or severe fat beneath the chin.
This is the strongest evidence within injection lipolysis, but the trials do not validate Aqualyx, Lemon Bottle or treatment of the abdomen, arms or thighs.
Product authorisation and availability are country-specific. Technique-related risks include nerve injury, ulceration and difficulty swallowing.
Separate branded mixture
Marketed for local fat reduction, often with claims of a gentler or “natural” mechanism.
Marketing descriptions are not a substitute for verified composition, manufacturing quality, pharmacology and controlled clinical outcomes.
Ask for sealed packaging, current ingredients, batch and legal status. US FDA action against one distributor is relevant safety context but should not be misreported as a UK ruling.
Systemic prescription weight-management medicines
Reduce appetite and support overall weight management in eligible people, alongside dietary, activity and clinical support.
These medicines can produce substantial overall weight loss and improve weight-related health for selected patients. They cannot choose where fat is lost and are not injected into the area someone wants to change.
They require a legitimate prescription, medical assessment and follow-up. MHRA strengthened pancreatitis warnings in 2026; pregnancy, contraception, surgery and other health issues need specific advice.
Results & trade-offs
A small local bulge and obesity are not the same clinical problem. Local lipolysis and GLP-1 medicines should not be sold as substitutes for one another.
Ask to see sealed packaging, verified active ingredients, batch details, patient information and source. “Fat dissolver” is not a sufficient answer.
Randomised trials support a specific ATX-101 formulation for submental fat. Aqualyx evidence is smaller; comparable controlled evidence for Lemon Bottle was not identified.
Local deoxycholate treatment can cause marked swelling and technique-related injury. GLP-1 medicines commonly cause gastrointestinal effects and have systemic contraindications and warnings.
Research in context
A defined prescription deoxycholic-acid formulation has trial evidence beneath the chin. Aqualyx has smaller product-specific studies, Lemon Bottle lacks comparable clinical evidence, and GLP-1 medicines treat weight systemically rather than dissolving a chosen fat pocket.
A 2023 meta-analysis found efficacy for ATX-101-type deoxycholic acid beneath the chin but also more local adverse effects; all five included trials had potential industry sponsorship bias. Aqualyx studies are much smaller, while GLP-1 evidence belongs to a separate obesity-medicine literature and cannot validate local lipolysis.
Safety
“Non-surgical” does not mean risk-free. The exact device or product, treatment area, practitioner and your health all change the risk.
If you feel seriously unwell or have trouble breathing, seek urgent medical help. This page cannot assess an individual complication.
Suitability
The treatment journey
Clarify whether the goal is local contouring or treatment of overweight or obesity. Assess the cause, health impact, medicines and alternatives before discussing a brand.
For local lipolysis, record ingredient, concentration, batch, expiry, supplier and injection map. For GLP-1 treatment, use an authorised product from a registered pharmacy under a legitimate prescription.
Local injection consent should cover swelling, infection and anatomical injury. GLP-1 consent should cover systemic effects, pregnancy, contraception, surgery, pancreatitis symptoms and the longer-term plan.
Assess local contour with standardised images or measurements; assess weight medicines with weight, health, tolerability and agreed clinical goals. Do not swap those endpoints.
Compare your options
Avoids injection and product risk; a cosmetic concern does not have to be treated.
Non-injectable local contouring with different risks, including PAH.
More invasive but can remove a more predictable volume in appropriately selected patients.
For overall weight and related health risks; may include nutrition, activity, behavioural support, medicines or surgery.
Take this to your consultation
Am I trying to change one local fat pocket or manage my overall weight and health?
What is the exact product, active ingredient, concentration and batch number?
What is its UK legal status, and can I read the official patient information?
What evidence supports this product in this exact body area?
Are you a regulated healthcare professional, and who is clinically accountable?
If this is a GLP-1 medicine, what diagnosis, monitoring, longer-term plan and stopping criteria apply?
Who can assess me urgently if I develop infection, skin injury, weakness or severe abdominal pain?
Source library
We link to guidance and papers so you can check the evidence yourself. A source appearing here does not mean every claim or conclusion in it is beyond debate.
US Food and Drug Administration
Describes scars, infections, deformities and painful nodules reported with unapproved injections.
US Food and Drug Administration
Identifies “LemonBottle Ampoule Solution” and other products sold by that US distributor as unapproved new drugs in the US.
Clinics / PubMed
Five RCTs supported submental efficacy but found more local adverse effects and potential industry bias.
Aesthetic Surgery Journal Open Forum / PubMed
Reviews uncommon serious events and how anatomy and injection technique contribute.
Journal of Ultrasonography / PMC
Small uncontrolled product-specific study: 7 women and 14 inner-knee fat pads, useful mainly for showing how limited the direct evidence is.
Clinical Case Reports / PubMed
Case report of necrosis, chronic infection and nodules after a product advertised as Aqualyx was injected too superficially.
National Institute for Health and Care Excellence
UK eligibility, use alongside diet and activity, and the 6-month response decision for NHS treatment.
MHRA / GOV.UK
Current UK safety advice covering authorised use, pregnancy, contraception, surgery, side effects and illegal supply.
MHRA / GOV.UK
UK Yellow Card route for suspected side effects, poor quality or counterfeit products.
Common questions
No. Evidence for a defined deoxycholic-acid medicine cannot be transferred to a differently formulated branded product. Ask for the exact ingredients and product status.
No. They are related through deoxycholate/deoxycholic-acid chemistry, but they are different formulations with different product status and evidence. The large randomised submental-fat programme for ATX-101 should not be presented as an Aqualyx trial.
Not in a like-for-like sense. Local lipolysis aims at a small subcutaneous pocket. GLP-1 and dual GIP/GLP-1 medicines act systemically and may be prescribed for weight management in eligible people. They cannot target one chosen area.
No. They contain different medicines or have different authorised uses. In the UK, Wegovy is semaglutide authorised for weight management, while Ozempic is a semaglutide product for type 2 diabetes; Mounjaro contains tirzepatide. A prescriber should choose by indication and individual circumstances.
Status is product-specific and can change. Ask the prescriber to identify the exact medicine or product and show its official information. If they cannot, do not proceed.
Evidence and anatomy differ. A formulation studied under the chin is not automatically proven for the abdomen, arms or thighs, and injection near nerves or vessels carries area-specific risk.
Seek medical care first. Suspected problems with medicines or medical devices can also be reported through the MHRA Yellow Card scheme; anyone can report.
Clinic directory
Directory information is separate from our editorial assessment. Inclusion is not a medical endorsement.
752 clinics
